Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, April 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 19 Mendeley

Summary Patents Dimensions citations

So far, Dimensions has found 6 publications that cite this research output.

6

The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.

Experience of the safety evaluation of the cellular immunotherapy application on basis LAC for canine oncological diseases treatment

Article in Russian veterinary journal (June 2019)

Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony‐stimulating factors in older patients with non‐Hodgkin lymphoma

Article in Cancer (December 2018)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis

Article in PLOS ONE (March 2017)